Inhibition of COX-1 attenuates the formation of thromboxane A2 and ameliorates the acute decrease in glomerular filtration rate in endotoxemic mice

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 4, 2015, Pages 332-340

  Mederle, Katharina ^a   Meurer, Manuel ^b   Castrop, Hayo ^a   Höcherl, Klaus ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Acute kidney injury; Cyclooxygenase; Inflammation; Lipopolysaccharide; Thromboxane

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; ENDOTOXIN; LIPOPOLYSACCHARIDE; THROMBOXANE A2; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; ENDOTOXIN, ESCHERICHIA COLI; MEMBRANE PROTEIN; PTGS1 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RENAL PROTECTION; SINGLE DRUG DOSE; THROMBOCYTE; TISSUE LEVEL; ACUTE KIDNEY INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; ENZYMOLOGY; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TIME;

ACUTE KIDNEY INJURY; ANIMALS; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOTOXEMIA; ENDOTOXINS; GLOMERULAR FILTRATION RATE; KIDNEY; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; SIGNAL TRANSDUCTION; THROMBOXANE A2; TIME FACTORS;

EID: 84939554028     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00567.2014     Document Type: Article

References (76)

1. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. Blood 106: 2417–2423, 2005.
2. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 8: 613–615, 2010.
3. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 9: 552–561, 2011.
4. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, Ni H, Lazarus AH, Freedman J, Semple JW. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 107: 637–641, 2006.
5. Badr KF, Kelley VE, Rennke HG, Brenner BM. Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney Int 30: 474–480, 1986.
6. Bauer J, Ripperger A, Frantz S, Ergun S, Schwedhelm E, Benndorf RA. Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation. Br J Pharmacol 171: 3115–3131, 2014.
7. Baylis C. Effects of administered thromboxanes on the intact, normal rat kidney. Renal Physiol 10: 110–121, 1987.
8. Bellomo R, Wan L, Langenberg C, Ishikawa K, May CN. Septic acute kidney injury: the glomerular arterioles. Contrib Nephrol 174: 98–107, 2011.
9. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336: 912–918, 1997.
10. Bhavaraju K, Georgakis A, Jin J, Gartner TK, Tomiyama Y, Nurden A, Nurden P, Kunapuli SP. Antagonism of P2Y(1)(2) reduces physiological thromboxane levels. Platelets 21: 604–609, 2010.
11. Bischoff A, Bucher M, Gekle M, Sauvant C. Differential effect of COX1 and COX2 inhibitors on renal outcomes following ischemic acute kidney injury. Am J Nephrol 40: 1–11, 2014.
12. Boffa JJ, Just A, Coffman TM, Arendshorst WJ. Thromboxane receptor mediates renal vasoconstriction and contributes to acute rena l failure in endotoxemic mice. J Am Soc Nephrol 15: 2358–2365, 2004.
13. Brenneis C, Maier TJ, Schmidt R, Hofacker A, Zulauf L, Jakobsson PJ, Scholich K, Geisslinger G. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J 20: 1352–1360, 2006.
14. Burnier M, Waeber B, Aubert JF, Nussberger J, Brunner HR. Effects of nonhypotensive endotoxemia in conscious rats: role of prostaglandins. Am J Physiol Heart Circ Physiol 254: H509–H516, 1988.
15. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289: 735–741, 1999.
16. Choi SH, Langenbach R, Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J 22: 1491–1501, 2008.
17. Cook JA, Wise WC, Tempel GE, Halushka PV. Exchange transfusions in rats with a perfluorated blood substitute: effect on thromboxane B2 levels during endotoxemia. Circ Shock 15: 193–204, 1985.
18. Cumming AD, Driedger AA, McDonald JW, Lindsay RM, Solez K, Linton AL. Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 11: 23–32, 1988.
19. de Stoppelaar SF, van’t Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost 112: 666–677, 2014.
20. Doi K, Yuen PS, Eisner C, Hu X, Leelahavanichkul A, Schnermann J, Star RA. Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol 20: 1217–1221, 2009.
21. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 164: 894–912, 2011.
22. Freund HR, Barcelli UO, Muggia-Sullam M, LaFrance R, Gallon LS, Fischer JE. Renal prostaglandin production is increased during abdominal sepsis in the rat and unaffected by the infusion of different amino acid formulations. J Surg Res 44: 99–103, 1988.
23. Frolich S, Olliges A, Kern N, Schreiber Y, Narumiya S, Nusing RM. Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition. Am J Physiol Renal Physiol 303: F209–F219, 2012.
24. Grandel U, Fink L, Blum A, Heep M, Buerke M, Kraemer HJ, Mayer K, Bohle RM, Seeger W, Grimminger F, Sibelius U. Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase- 2-derived thromboxane production. Circulation 102: 2758–2764, 2000.
25. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 132: 1565–1573, 2001.
26. Hagiwara S, Iwasaka H, Hasegawa A, Oyama M, Imatomi R, Uchida T, Noguchi T. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 35: 289–292, 2011.
27. Haupt MT, Jastremski MS, Clemmer TP, Metz CA, Goris GB. Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit Care Med 19: 1339–1347, 1991.
28. Hayashi K, Loutzenhiser R, Epstein M. Direct evidence that thromboxane mimetic U44069 preferentially constricts the afferent arteriole. J Am Soc Nephrol 8: 25–31, 1997.
29. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349: 617–620, 1991.
30. Hocherl K, Dreher F, Kurtz A, Bucher M. Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension 40: 947–953, 2002.
31. Hocherl K, Endemann D, Kammerl MC, Grobecker HF, Kurtz A. Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol 136: 1117–1126, 2002.
32. Hocherl K, Schmidt C, Bucher M. COX-2 inhibition attenuates endotoxin- induced downregulation of organic anion transporters in the rat renal cortex. Kidney Int 75: 373–380, 2009.
33. Hoozemans JJ, Veerhuis R, Janssen I, van Elk EJ, Rozemuller AJ, Eikelenboom P. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer’s disease. Brain Res 951: 218–226, 2002.
34. Ichitani Y, Holmberg K, Maunsbach AB, Haeggstrom JZ, Samuelsson B, De Witt D, Hokfelt T. Cyclooxygenase-1 and cyclooxygenase-2 expression in rat kidney and adrenal gland after stimulation with systemic lipopolysaccharide: in situ hybridization and immunocytochemical studies. Cell Tissue Res 303: 235–252, 2001.
35. Ito T, Asai F, Oshima T, Kobayashi S. Role of activated platelets in endotoxin-induced DIC in rats. Thromb Res 59: 735–747, 1990.
36. Khan RZ, Badr KF. Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock. Nephrol Dial Transplant 14: 814–818, 1999.
37. Kikeri D, Pennell JP, Hwang KH, Jacob AI, Richman AV, Bourgoignie JJ. Endotoxemic acute renal failure in awake rats. Am J Physiol Renal Fluid Electrolyte Physiol 250: F1098–F1106, 1986.
38. Klein T, Neuhaus K, Reutter F, Nusing RM. Generation of 8-epiprostaglandin F(2alpha) in isolated rat kidney glomeruli by a radicalindependent mechanism. Br J Pharmacol 133: 643–650, 2001.
39. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 59: 2243–2249, 2001.
40. Kon V, Badr KF. Biological actions and pathophysiologic significance of endothelin in the kidney. Kidney Int 40: 1–12, 1991.
41. Leach M, Hamilton LC, Olbrich A, Wray GM, Thiemermann C. Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone. Br J Pharmacol 124: 586–592, 1998.
42. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 278: 30725–30731, 2003.
43. Linden MD. Platelet physiology. Methods Mol Biol 992: 13–30, 2013.
44. Liverani E, Rico MC, Yaratha L, Tsygankov AY, Kilpatrick LE, Kunapuli SP. LPS-induced systemic inflammation is more severe in P2Y12 null mice. J Leukoc Biol 95: 313–323, 2014.
45. Lopez-Parra M, Claria J, Planaguma A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jimenez W, Altuna R, Arroyo V, Rivera F, Rodes J. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 135: 891–900, 2002.
46. Lugon JR, Boim MA, Ramos OL, Ajzen H, Schor N. Renal function and glomerular hemodynamics in male endotoxemic rats. Kidney Int 36: 570–575, 1989.
47. Matzdorf C, Kurtz A, Hocherl K. COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys. Am J Physiol Renal Physiol 292: F1782–F1790, 2007.
48. Mederle K, Schweda F, Kattler V, Doblinger E, Miyata K, Hocherl K, Oike Y, Castrop H. The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension. Crit Care 17: R130, 2013.
49. Nasrallah R, Clark J, Hebert RL. Prostaglandins in the kidney: developments since Y2K. Clin Sci (Lond) 113: 297–311, 2007.
50. Nduka OO, Parrillo JE. The pathophysiology of septic shock. Crit Care Nurs Clin North Am 23: 41–66, 2011.
51. Ogawa T, Tomomasa T, Hikima A, Kobayashi Y, Nakano K, Fukabori Y, Morikawa A. Developmental changes in cyclooxygenase mRNA expression in the kidney of rats. Pediatr Nephrol 16: 618–622, 2001.
52. Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, Eckardt KU, Loeffler M, John S, German Competence Network S. Acute renal failure in patients with severe sepsis and septic shock–a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 23: 904–909, 2008.
53. Patrignani P, Di Febbo C, Tacconelli S, Moretta V, Baccante G, Sciulli MG, Ricciotti E, Capone ML, Antonucci I, Guglielmi MD, Stuppia L, Porreca E. Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. Blood 107: 3572–3574, 2006.
54. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 274: 29108–29114, 1999.
55. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347–1365, 1997.
56. Pu Q, Wiel E, Corseaux D, Bordet R, Azrin MA, Ezekowitz MD, Lund N, Jude B, Vallet B. Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock. Crit Care Med 29: 1181–1188, 2001.
57. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31: 986–1000, 2011.
58. Ruetten H, Thiemermann C. Effect of selective blockade of endothelin ETB receptors on the liver dysfunction and injury caused by endotoxaemia in the rat. Br J Pharmacol 119: 479–486, 1996.
59. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83: 536–545, 2008.
60. Schreiber A, Shulhevich Y, Geraci S, Hesser J, Stsepankou D, Neudecker S, Koenig S, Heinrich R, Hoecklin F, Pill J, Friedemann J, Schweda F, Gretz N, Schock-Kusch D. Transcutaneous measurement of renal function in conscious mice. Am J Physiol Renal Physiol 303: F783–F788, 2012.
61. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 351: 159–169, 2004.
62. Seidel M, Winning J, Claus RA, Bauer M, Losche W. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost 7: 1030–1032, 2009.
63. Sheu JR, Hung WC, Wu CH, Ma MC, Kan YC, Lin CH, Lin MS, Luk HN, Yen MH. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. Circulation 99: 3056–3062, 1999.
64. Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 81: 819–825, 2012.
65. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95: 13313–13318, 1998.
66. Staehr M, Madsen K, Vanhoutte PM, Hansen PB, Jensen BL. Disruption of COX-2 and eNOS does not confer protection from cardiovascular failure in lipopolysaccharide-treated conscious mice and isolated vascular rings. Am J Physiol Regul Integr Comp Physiol 301: R412–R420, 2011.
67. Steiner AA, Hunter JC, Phipps SM, Nucci TB, Oliveira DL, Roberts JL, Scheck AC, Simmons DL, Romanovsky AA. Cyclooxygenase-1 or -2–which one mediates lipopolysaccharide-induced hypothermia? Am J Physiol Regul Integr Comp Physiol 297: R485–R494, 2009.
68. Tempel GE, Cook JA, Wise WC, Halushka PV, Corral D. Improvement in organ blood flow by inhibition of thromboxane synthetase during experimental endotoxic shock in the rat. J Cardiovasc Pharmacol 8: 514–519, 1986.
69. Tokes-Fuzesi M, Woth G, Ernyey B, Vermes I, Muhl D, Bogar L, Kovacs GL. Microparticles and acute renal dysfunction in septic patients. J Crit Care 28: 141–147, 2013.
70. van Lambalgen AA, Bouriquet N, Casellas D. Effects of endotoxin on tone and pressure-responsiveness of preglomerular juxtamedullary vessels. Pflügers Arch 432: 574–577, 1996.
71. Wallace JL. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 15: 691–703, 2001.
72. Wang W, Falk SA, Jittikanont S, Gengaro PE, Edelstein CL, Schrier RW. Protective effect of renal denervation on normotensive endotoxemiainduced acute renal failure in mice. Am J Physiol Renal Physiol 283: F583–F587, 2002.
73. Ware LB, Fessel JP, May AK, Roberts LJ. Plasma biomarkers of oxidant stress and development of organ failure in severe sepsis. Shock 36: 12–17, 2011.
74. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, Claus RA, Bauer M, Losche W. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 20: 50–57, 2009.
75. Zhang G, Han J, Welch EJ, Ye RD, Voyno-Yasenetskaya TA, Malik AB, Du X, Li Z. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 182: 7997–8004, 2009.
76. Zhang W, Zhang Y, Edvinsson L, Xu CB. Transcriptional downregulation of thromboxane A(2) receptor expression via activation of MAPK ERK1/2, p38/NF-kappaB pathways. J Vasc Res 46: 162–174, 2009.